retatrutide
How Retatrutide's Peptide Class Is Described in Research Catalogues
A look at how research catalogues label retatrutide's peptide class, what the terminology means, and how it differs from single-receptor listings.
Medically reviewed by Thomas Kline, PhD, biochemist — Last reviewed
Thomas Kline, PhD is a biochemist with a doctorate in structural biochemistry from MIT and 16 years of research in GLP receptor biology and synthetic peptide analog pharmacology.
Research catalogues typically describe retatrutide’s peptide class as a triple agonist peptide, referencing its designed activity across three distinct receptor targets rather than one. Understanding how retatrutide’s peptide class is described in research catalogues helps clarify why its listings read differently from single-target compounds on the same supplier pages, and why the classification language matters when comparing specs across vendors.
What “Triple Agonist” Means in a Listing
Most peptide catalogues sort compounds by receptor target because that is the detail researchers scan for first. A listing for retatrutide will usually name three receptor pathways in its classification line, distinguishing it from compounds that act on a single pathway. Catalogues use this shorthand because it communicates, in a few words, the structural design intent behind the molecule without requiring a full sequence readout.
This differs from how older GLP-family peptides are classified. A single-target compound is generally listed with one receptor named, sometimes alongside a note on selectivity. When a catalogue instead lists three targets for one peptide, it signals that the molecule was synthesized to interact with multiple receptor families, which is the defining trait researchers look for when sorting multi-target analogs from single-target ones.
Where This Classification Appears on a Product Page
Retatrutide’s peptide class is described in research catalogues in a few consistent places: the product title, a classification or “category” field near the top of the listing, and sometimes a short summary line beneath the vial specifications. Some catalogues also group compounds into filterable categories on their site navigation, placing multi-target peptides in a separate bucket from single-target ones.
A typical catalogue entry separates the classification language from the analytical data. The classification line answers “what kind of peptide is this,” while the certificate of analysis (COA) answers “what is actually in this vial.” Both matter, but they serve different questions, and conflating them is a common source of confusion when comparing listings across suppliers.
| Catalogue field | What it typically states |
|---|---|
| Classification / category | Receptor target family, e.g. triple agonist peptide |
| Product title | Compound name, sometimes with class descriptor appended |
| Specification table | Molecular weight, sequence length, vial mass |
| COA | Purity percentage, identity confirmation method, lot number |
Why the Terminology Varies Between Suppliers
Not every catalogue uses identical wording. Some list retatrutide under a broader “GLP research peptides” category with the triple-target detail mentioned in the product description rather than a dedicated field. Others use more technical receptor-pathway names directly in the classification tag. Neither approach is wrong; catalogues are organized around what makes their own site easiest to browse, and there is no single mandated taxonomy across the industry.
This variation is worth noting when cross-referencing listings, because a search for one classification term on one site may not surface the equivalent product on another site that uses different wording for the same underlying molecule. Reading the specification table and COA alongside the classification tag is the more reliable way to confirm two listings refer to the same compound, rather than relying on category labels alone.
Reading Vial Specs Alongside the Classification
Once the classification tag has told a researcher what type of peptide is listed, the vial specification section is where the concentration-relevant numbers live. A catalogue entry usually states vial mass in milligrams, and separately notes the recommended volume of bacteriostatic water for reconstitution, if the supplier provides mixing guidance at all.
The concentration math itself is simple division: vial mass divided by the volume of diluent added gives concentration in mg/mL. For example, a 10 mg vial reconstituted with 2 mL of bacteriostatic water yields a concentration of 5 mg/mL. Since 1 mg equals 1000 mcg, that same solution also equals 5000 mcg/mL. On a U-100 insulin syringe, where 1 mL corresponds to 100 unit markings, each unit drawn on that syringe corresponds to 0.05 mg (50 mcg) of the reconstituted solution. These figures describe how the math works once a concentration and syringe type are known; they are not directions for use. Researchers who want to verify reconstitution math independently can cross-check the arithmetic with a tool such as peptcalc.com.
Cross-Referencing Class Terminology Across Sources
Because catalogue wording is not standardized, it helps to check more than one source when confirming how a compound is classified. Independent research reference sites often use more consistent terminology than individual seller pages, since they are not organizing content around a shop’s category filters. For that kind of cross-reference, a page like heezresearch.com/research/retatrutide/ lays out the classification and spec data in a single reference format, which is useful when a supplier’s own listing is thin on detail.
Comparing terminology across supplier catalogues in the same cluster is also useful, and sites such as retainfo.com and retaonline.net cover overlapping classification and sourcing material from different angles, which can help confirm that the same class terminology is being applied consistently.
Summary
Retatrutide’s peptide class is described in research catalogues primarily through a classification or category field that names its multi-receptor target design, most often summarized as a triple agonist peptide. This label sits alongside, but is distinct from, the specification table and COA that define a specific vial’s measurable properties. Because catalogue wording varies by supplier, cross-referencing the classification tag against the spec sheet and an independent reference source is the more reliable way to confirm what a given listing is actually describing.